BG64940B1 - Метод за подобряване на ефикасността на антитуморни средства - Google Patents
Метод за подобряване на ефикасността на антитуморни средства Download PDFInfo
- Publication number
- BG64940B1 BG64940B1 BG106057A BG10605701A BG64940B1 BG 64940 B1 BG64940 B1 BG 64940B1 BG 106057 A BG106057 A BG 106057A BG 10605701 A BG10605701 A BG 10605701A BG 64940 B1 BG64940 B1 BG 64940B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- erythropoietin
- cisplatin
- hematocrit
- group
- tumor
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 15
- 230000002708 enhancing effect Effects 0.000 title abstract description 4
- 238000005534 hematocrit Methods 0.000 claims abstract description 42
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 76
- 102000003951 Erythropoietin Human genes 0.000 claims description 75
- 108090000394 Erythropoietin Proteins 0.000 claims description 75
- 229940105423 erythropoietin Drugs 0.000 claims description 74
- 229960004316 cisplatin Drugs 0.000 claims description 58
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 57
- 239000002246 antineoplastic agent Substances 0.000 claims description 35
- 239000003623 enhancer Substances 0.000 claims description 15
- 150000003058 platinum compounds Chemical class 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 7
- 229960004562 carboplatin Drugs 0.000 claims description 6
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 claims 2
- GZXVJRNJTCNEIL-UHFFFAOYSA-L platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O GZXVJRNJTCNEIL-UHFFFAOYSA-L 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 63
- 230000000694 effects Effects 0.000 abstract description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 229910052697 platinum Inorganic materials 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 10
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 7
- 102100036509 Erythropoietin receptor Human genes 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 230000010437 erythropoiesis Effects 0.000 description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000002710 gonadal effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 206010024264 Lethargy Diseases 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- YCAGGFXSFQFVQL-UHFFFAOYSA-N Endothion Chemical compound COC1=COC(CSP(=O)(OC)OC)=CC1=O YCAGGFXSFQFVQL-UHFFFAOYSA-N 0.000 description 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- -1 transition metal salts Chemical class 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 235000000621 Bidens tripartita Nutrition 0.000 description 1
- 240000004082 Bidens tripartita Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241001456553 Chanodichthys dabryi Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 208000006637 fused teeth Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/300,124 US6171620B1 (en) | 1999-04-27 | 1999-04-27 | Method of enhancing the efficacy of anti-tumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG106057A BG106057A (en) | 2002-04-30 |
| BG64940B1 true BG64940B1 (bg) | 2006-10-31 |
Family
ID=23157813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG106057A BG64940B1 (bg) | 1999-04-27 | 2001-10-26 | Метод за подобряване на ефикасността на антитуморни средства |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6171620B1 (https=) |
| EP (1) | EP1212068A4 (https=) |
| JP (1) | JP2002542296A (https=) |
| KR (1) | KR100693796B1 (https=) |
| CN (1) | CN1188137C (https=) |
| AU (1) | AU781301B2 (https=) |
| BG (1) | BG64940B1 (https=) |
| BR (1) | BR0010082A (https=) |
| CA (1) | CA2368618C (https=) |
| HU (1) | HUP0200840A3 (https=) |
| IL (1) | IL146012A0 (https=) |
| MX (1) | MXPA01010899A (https=) |
| NO (1) | NO20015227L (https=) |
| NZ (1) | NZ514521A (https=) |
| PL (1) | PL350918A1 (https=) |
| RU (1) | RU2271829C2 (https=) |
| WO (1) | WO2000064455A1 (https=) |
| ZA (1) | ZA200108012B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003531179A (ja) | 2000-04-26 | 2003-10-21 | クイーンズ ユニバーシティ アット キングストン | 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法 |
| US20050142217A1 (en) * | 2000-04-26 | 2005-06-30 | Adams Michael A. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| US7678391B2 (en) * | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| DE60332358D1 (de) * | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| HRP20150037T4 (hr) | 2003-04-08 | 2022-09-02 | Progenics Pharmaceuticals, Inc. | Farmaceutske formulacije koje sadrže metilnaltrekson |
| DE10361813A1 (de) * | 2003-12-30 | 2005-09-08 | Bionethos Holding Gmbh | Verfahren zur Regeneration von Gewebe |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| ES2714198T3 (es) * | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| CN101678079B (zh) | 2006-11-28 | 2013-12-25 | 韩诺生物制约株式会社 | 修饰的促红细胞生成素多肽及其治疗用途 |
| MX2009010550A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
| SI2565195T1 (sl) | 2007-03-29 | 2015-09-30 | Wyeth Llc | Periferalni opioidni receptorji in antagonisti in njih uporaba |
| CL2008000905A1 (es) | 2007-03-29 | 2008-08-22 | Progenics Pharm Inc | Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena. |
| EP2240489A1 (en) | 2008-02-06 | 2010-10-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| CA2723621A1 (en) * | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| PL230756B1 (pl) * | 2015-09-11 | 2018-12-31 | Univ Medyczny W Bialymstoku | Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu |
| WO2019083023A1 (ja) * | 2017-10-26 | 2019-05-02 | 国立大学法人筑波大学 | 癌の治療に使用するための組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
| JP2632014B2 (ja) * | 1988-03-03 | 1997-07-16 | 中外製薬株式会社 | 骨髄機能障害性貧血治療剤 |
| RU2111750C1 (ru) * | 1995-02-23 | 1998-05-27 | Институт элементоорганических соединений РАН | Модификатор для противоопухолевой терапии |
| JPH1067678A (ja) * | 1996-06-20 | 1998-03-10 | Chugai Pharmaceut Co Ltd | 肝疾患治療用医薬組成物 |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
-
1999
- 1999-04-27 US US09/300,124 patent/US6171620B1/en not_active Expired - Fee Related
-
2000
- 2000-04-24 JP JP2000613446A patent/JP2002542296A/ja active Pending
- 2000-04-24 MX MXPA01010899A patent/MXPA01010899A/es active IP Right Grant
- 2000-04-24 IL IL14601200A patent/IL146012A0/xx unknown
- 2000-04-24 PL PL00350918A patent/PL350918A1/xx not_active Application Discontinuation
- 2000-04-24 WO PCT/US2000/011000 patent/WO2000064455A1/en not_active Ceased
- 2000-04-24 EP EP00926315A patent/EP1212068A4/en not_active Withdrawn
- 2000-04-24 HU HU0200840A patent/HUP0200840A3/hu unknown
- 2000-04-24 BR BR0010082-0A patent/BR0010082A/pt not_active Application Discontinuation
- 2000-04-24 CA CA2368618A patent/CA2368618C/en not_active Expired - Fee Related
- 2000-04-24 CN CNB008065659A patent/CN1188137C/zh not_active Expired - Fee Related
- 2000-04-24 KR KR1020017012929A patent/KR100693796B1/ko not_active Expired - Fee Related
- 2000-04-24 RU RU2001131894/14A patent/RU2271829C2/ru not_active IP Right Cessation
- 2000-04-24 NZ NZ514521A patent/NZ514521A/en not_active IP Right Cessation
- 2000-04-24 AU AU44863/00A patent/AU781301B2/en not_active Ceased
- 2000-12-19 US US09/740,501 patent/US6426094B2/en not_active Expired - Fee Related
-
2001
- 2001-09-28 ZA ZA200108012A patent/ZA200108012B/xx unknown
- 2001-10-25 NO NO20015227A patent/NO20015227L/no not_active Application Discontinuation
- 2001-10-26 BG BG106057A patent/BG64940B1/bg unknown
-
2002
- 2002-07-26 US US10/206,533 patent/US6620779B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6426094B2 (en) | 2002-07-30 |
| BR0010082A (pt) | 2002-01-15 |
| HUP0200840A2 (hu) | 2002-07-29 |
| WO2000064455A1 (en) | 2000-11-02 |
| PL350918A1 (en) | 2003-02-10 |
| JP2002542296A (ja) | 2002-12-10 |
| EP1212068A4 (en) | 2007-03-14 |
| US6620779B2 (en) | 2003-09-16 |
| NO20015227D0 (no) | 2001-10-25 |
| ZA200108012B (en) | 2003-03-26 |
| CA2368618A1 (en) | 2000-11-02 |
| CA2368618C (en) | 2011-03-01 |
| KR20020000557A (ko) | 2002-01-05 |
| CN1352561A (zh) | 2002-06-05 |
| NZ514521A (en) | 2003-07-25 |
| BG106057A (en) | 2002-04-30 |
| HUP0200840A3 (en) | 2003-04-28 |
| US20010000730A1 (en) | 2001-05-03 |
| AU781301B2 (en) | 2005-05-12 |
| RU2271829C2 (ru) | 2006-03-20 |
| NO20015227L (no) | 2001-12-27 |
| MXPA01010899A (es) | 2003-06-24 |
| KR100693796B1 (ko) | 2007-03-12 |
| EP1212068A1 (en) | 2002-06-12 |
| AU4486300A (en) | 2000-11-10 |
| US6171620B1 (en) | 2001-01-09 |
| US20020198153A1 (en) | 2002-12-26 |
| IL146012A0 (en) | 2002-07-25 |
| CN1188137C (zh) | 2005-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG64940B1 (bg) | Метод за подобряване на ефикасността на антитуморни средства | |
| Abdel-Razeq et al. | Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia | |
| KR102713072B1 (ko) | 두경부암 치료를 위한 egfr 저해제 | |
| ES2270586T3 (es) | Compuestos y metodos para el tratamiento de tumores. | |
| US20240024319A1 (en) | Combination of bi853520 with chemotherapeutic drugs | |
| EP3042669B1 (en) | Antitumor agent and antitumor effect enhancer | |
| KR20030014228A (ko) | 배합 화학요법 | |
| JP2024125139A (ja) | アズブジンを含む抗腫瘍医薬組成物 | |
| WO2021110136A1 (en) | Pharmaceutical combination and use thereof | |
| Ford et al. | Strategies to optimize the use of erythropoietin and iron therapy in oncology patients. | |
| Gonzalez et al. | Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma | |
| CN112168971B (zh) | 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用 | |
| KR20240138493A (ko) | Met 저해제 및 k-ras 저해제를 포함하는 암 예방 또는 치료용 조성물 | |
| HK40113623A (zh) | [(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸(罗沙司他)用於治疗化疗诱导的贫血(cia) | |
| HK40114211A (zh) | [(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸(罗沙司他)用於治疗化疗诱导的贫血(cia) | |
| EP4694912A2 (en) | Use of beta-catenin antagonist and immunomodulator | |
| US20210346520A1 (en) | Methods of using intravenous rexin-g: a tumor-targeted retrovector encoding a dominant-negative cyclin g1 (ccng1) inhibitor for advanced pancreatic cancer | |
| Kono et al. | MO25-5 Phase II study of 54 Gy accelerated hyperfractionated thoracic radiotherapy in limited-stage small-cell lung cancer | |
| HK40104393A (zh) | [(4-羟基-1-甲基-7-苯氧基异喹啉-3-羰基)氨基]乙酸(罗沙司他)用於治疗化疗诱导的贫血(cia) | |
| Henry | Anemia in patients with cancer or undergoing cancer therapy: impact and current treatment practice | |
| KR20260049608A (ko) | 아자 2 고리형 화합물과 항안드로겐제를 사용한 암 병용 요법 | |
| CN114748630A (zh) | 具有改善功效的铂类抗癌药物组合物及其用途 | |
| Mita et al. | 409 AP23573, an mTOR inhibitor, administered IV daily× 5 every other week in patients with refractory or advanced malignancies—a phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study | |
| Martinelli et al. | Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment | |
| CN112168960A (zh) | 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用 |